Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/33767
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorArrambide, Georgina-
dc.contributor.authorLlaneza-González, Miguel Ángel-
dc.contributor.authorCosta-Frossard França, Lucienne-
dc.contributor.authorMeca-Lallana, Virginia-
dc.contributor.authorFernández- Díaz, Eva-
dc.contributor.authorMoreno Torres, Irene-
dc.contributor.authorGarcía-Domínguez, Jose Manuel-
dc.contributor.authorOrtega Suero, Gloria-
dc.contributor.authorAyuso-Peralta, Lucia-
dc.contributor.authorGomez-Moreno, Mayra-
dc.contributor.authorSotoca-Fernández, Javier J.-
dc.contributor.authorCaminero-Rodríguez, Ana Belén-
dc.contributor.authorRodríguez de Antonio, Luis A.-
dc.contributor.authorCorujo-Suárez, Marcial-
dc.contributor.authorOtano-Martínez, María A.-
dc.contributor.authorPérez-Miralles, Francisco Carlos-
dc.contributor.authorReyes-Garrido, Virginia-
dc.contributor.authorAyuso-Blanco, Teresa-
dc.contributor.authorBalseiro-Gómez, José Jesús-
dc.contributor.authorMuñoz Pasadas, Mercedes-
dc.contributor.authorPérez-Molina, Inmaculada-
dc.contributor.authorArnal-García, Carmen-
dc.contributor.authorDomingo-Santos, Angela-
dc.contributor.authorGuijarro-Castro, Cristina-
dc.contributor.authorÍñiguez-Martínez, Cristina-
dc.contributor.authorTéllez Lara, Nieves-
dc.contributor.authorCastellanos Pinedo, Fernando-
dc.contributor.authorCastillo-Trivino, Tamara-
dc.contributor.authorCerdán-Santacruz, Debora María-
dc.contributor.authorPerez-Sempere, Angel-
dc.contributor.authorSebastián Torres, Berta-
dc.contributor.authorÁlvarez de Arcaya, Amaya-
dc.contributor.authorCosta-Arpín, Eva-
dc.contributor.authorDurán-Ferreras, Eduardo-
dc.contributor.authorFragoso-Martínez, Marta-
dc.contributor.authorGonzález Platas, Montserrat-
dc.contributor.authorLandete, Lamberto-
dc.contributor.authorMillán-Pascual, Jorge-
dc.contributor.authorOreja-Guevara, Celia-
dc.contributor.authorMECA-LALLANA, JOSE EUSTASIO-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-11-04T10:30:08Z-
dc.date.available2024-11-04T10:30:08Z-
dc.date.created2021-
dc.identifier.citationNeurol Neuroimmunol Neuroinflamm 2021;8:e1024es_ES
dc.identifier.issn2332-7812-
dc.identifier.urihttps://hdl.handle.net/11000/33767-
dc.description.abstractObjective To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of diseasemodifying treatments. Methods Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome. Results Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04–1.17) as the only independent risk factor for a fatal outcome. Conclusions This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent12es_ES
dc.language.isoenges_ES
dc.publisherWolters Kluwer Health/Lippincott Williams & Wilkinses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEsclerosis múltiplees_ES
dc.subjectCOVID-19es_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicinaes_ES
dc.titleSARS-CoV-2 Infection in Multiple Sclerosis. Results of the Spanish Neurology Society Registryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1212/NXI.0000000000001024es_ES
Aparece en las colecciones:
Artículos Medicina Clínica


Vista previa

Ver/Abrir:
 SARS-CoV-2 Infection in Multiple Sclerosis.pdf

290,55 kB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.